TWI382022B - 二甲氧基剋癌易（ｄｏｃｅｔａｘｅｌ）之丙酮溶劑合物及其製法 - Google Patents
二甲氧基剋癌易（ｄｏｃｅｔａｘｅｌ）之丙酮溶劑合物及其製法 Download PDFInfo
- Publication number
- TWI382022B TWI382022B TW093128097A TW93128097A TWI382022B TW I382022 B TWI382022 B TW I382022B TW 093128097 A TW093128097 A TW 093128097A TW 93128097 A TW93128097 A TW 93128097A TW I382022 B TWI382022 B TW I382022B
- Authority
- TW
- Taiwan
- Prior art keywords
- acetone
- hydroxy
- water
- mixture
- dimethoxy
- Prior art date
Links
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 title claims description 82
- 239000012453 solvate Substances 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
- 229960003668 docetaxel Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000013078 crystal Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 claims description 3
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- ZHXYSICWKISVCX-VZXYPILPSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid;propan-2-one Chemical compound CC(C)=O.CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZHXYSICWKISVCX-VZXYPILPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0311016A FR2859996B1 (fr) | 2003-09-19 | 2003-09-19 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200524891A TW200524891A (en) | 2005-08-01 |
| TWI382022B true TWI382022B (zh) | 2013-01-11 |
Family
ID=34224354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093128097A TWI382022B (zh) | 2003-09-19 | 2004-09-17 | 二甲氧基剋癌易（ｄｏｃｅｔａｘｅｌ）之丙酮溶劑合物及其製法 |
Country Status (37)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009533330A (ja) * | 2006-03-21 | 2009-09-17 | ドクター レディズ ラボラトリーズ リミテッド | ドセタキセルの多形体およびプロセス |
| US7855591B2 (en) * | 2006-06-07 | 2010-12-21 | Atmel Corporation | Method and system for providing a charge pump very low voltage applications |
| US7652522B2 (en) * | 2006-09-05 | 2010-01-26 | Atmel Corporation | High efficiency low cost bi-directional charge pump circuit for very low voltage applications |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| AU2013205442B2 (en) * | 2008-01-17 | 2016-05-12 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
| FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| JP5588983B2 (ja) | 2008-08-11 | 2014-09-10 | ウェルズ ファーゴ バンク ナショナル アソシエイション | マルチアームポリマーアルカノエートコンジュゲート |
| FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| AU2015200149B2 (en) * | 2009-10-29 | 2016-12-01 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| KR101712231B1 (ko) * | 2009-10-29 | 2017-03-03 | 아벤티스 파마 소시에떼아노님 | 카바지탁셀의 신규한 항종양 용도 |
| CA2708489A1 (en) * | 2009-10-29 | 2011-04-29 | Aventis Pharma S.A. | Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012142117A1 (en) | 2011-04-12 | 2012-10-18 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
| WO2013024495A1 (en) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Pharmaceutical formulations of cabazitaxel |
| TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| CN103906747A (zh) | 2011-10-31 | 2014-07-02 | 台湾神隆股份有限公司 | 卡巴他赛及其中间体的制备方法 |
| WO2013065070A1 (en) | 2011-11-01 | 2013-05-10 | Fresenius Kabi Encology Ltd. | Amorphous form of cabazitaxel and process for its preparation |
| ES2716799T3 (es) * | 2011-11-28 | 2019-06-17 | Fresenius Kabi Oncology Ltd | Forma cristalina de cabazitaxel y proceso para la preparación de la misma |
| EP2791122B1 (en) | 2011-12-13 | 2019-01-23 | Aventis Pharma S.A. | Crystalline form of cabazitaxel and process for preparing the same |
| US9403785B2 (en) | 2012-01-03 | 2016-08-02 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| JP2015509929A (ja) * | 2012-02-10 | 2015-04-02 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの新規な小児への使用 |
| US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102675257B (zh) * | 2012-05-10 | 2014-07-02 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
| CN102746258B (zh) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| EP2880021A4 (en) | 2012-07-31 | 2015-06-17 | Yung Shin Pharm Ind Co Ltd | AMORPHIC CABACITAXEL |
| EP2884963B1 (en) | 2012-08-15 | 2017-12-27 | Yung Shin Pharm. Ind. Co. Ltd. | Stable pharmaceutical formulation of cabazitaxel |
| CN103664836B (zh) * | 2012-09-20 | 2016-04-20 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| EP2743264A1 (en) | 2012-12-13 | 2014-06-18 | INDENA S.p.A. | New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| CN103910696B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛异丙醚合物及其结晶 |
| CN103910698B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛丙酮合物及其结晶 |
| EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015000165A1 (zh) * | 2013-07-04 | 2015-01-08 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| CN104277014A (zh) * | 2013-07-04 | 2015-01-14 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| EP2865675A1 (en) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| EP2865674A1 (en) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| CN103601704B (zh) * | 2013-11-22 | 2015-05-06 | 石家庄智恒医药科技有限公司 | 无定形卡巴他赛的制备 |
| WO2016113752A2 (en) | 2015-01-12 | 2016-07-21 | Emcure Pharmaceuticals Limited | Liquid formulation of cabazitaxel |
| JP6841772B2 (ja) * | 2015-02-17 | 2021-03-10 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 前立腺癌の処置におけるカバジタキセルの使用 |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
| EP3548497A4 (en) | 2016-11-29 | 2020-09-02 | Censa Pharmaceuticals Inc. | SEPIAPTERIN POLYMORPHS AND THEIR SALTS |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| EP3675863A4 (en) | 2017-09-01 | 2021-01-27 | PTC Therapeutics MP, Inc. | PHARMACEUTICAL COMPOSITIONS WITH SEPIAPTERIN AND USES THEREOF |
| BR112020024329A2 (pt) | 2018-05-30 | 2021-02-23 | Ptc Therapeutics Mp, Inc. | composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin |
| MD3801536T2 (ro) | 2018-05-30 | 2024-11-30 | Ptc Therapeutics Mp Inc | Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei |
| WO2020249507A1 (en) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
| EP3808345A1 (en) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
| EP3797834A1 (en) | 2019-09-25 | 2021-03-31 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US20020038038A1 (en) * | 1995-03-27 | 2002-03-28 | Aventis Pharma S.A. | Methods for treating pathological conditions of abnormal cell proliferation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722191B1 (fr) * | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
| DE4425978C1 (de) * | 1994-07-22 | 1995-11-23 | Karlsruhe Forschzent | Verfahren zur Herstellung keramischer Mikrostrukturen |
| FR2745814B1 (fr) * | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| EP0982027A1 (en) * | 1998-08-17 | 2000-03-01 | Aventis Pharma S.A. | Taxoid derivatives for treating abnormal cell proliferation of the brain |
| US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| US6136989A (en) * | 1998-12-30 | 2000-10-24 | Phytogen Life Sciences, Incorporated | Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material |
| US5969165A (en) * | 1999-01-07 | 1999-10-19 | 508037 (Nb) Inc. | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
| JP2002544269A (ja) * | 1999-05-17 | 2002-12-24 | ブリストル−マイヤーズ スクイブ カンパニー | パクリタキセルおよびパクリタキセル類似体の製造におけるシリルエーテルの切断のための新規反応条件 |
| RU2284328C2 (ru) * | 2001-11-29 | 2006-09-27 | Дайити Фармасьютикал Ко., Лтд. | Кристаллы производных таксана и способ их получения |
-
2003
- 2003-09-19 FR FR0311016A patent/FR2859996B1/fr not_active Expired - Lifetime
-
2004
- 2004-08-19 PE PE2004000799A patent/PE20050870A1/es not_active Application Discontinuation
- 2004-09-16 PL PL04787385T patent/PL1667986T3/pl unknown
- 2004-09-16 WO PCT/FR2004/002344 patent/WO2005028462A1/fr not_active Ceased
- 2004-09-16 AR ARP040103329A patent/AR045667A1/es not_active Application Discontinuation
- 2004-09-16 ME MEP-2008-117A patent/ME00054B/me unknown
- 2004-09-16 UA UAA200604360A patent/UA87115C2/ru unknown
- 2004-09-16 SI SI200432016T patent/SI1667986T1/sl unknown
- 2004-09-16 PT PT4787385T patent/PT1667986E/pt unknown
- 2004-09-16 BR BRPI0414492A patent/BRPI0414492A8/pt not_active Application Discontinuation
- 2004-09-16 JP JP2006526663A patent/JP5010279B2/ja not_active Expired - Lifetime
- 2004-09-16 CN CNB200480026128XA patent/CN100429207C/zh not_active Expired - Lifetime
- 2004-09-16 PA PA20048612401A patent/PA8612401A1/es unknown
- 2004-09-16 MX MXPA06002639A patent/MXPA06002639A/es active IP Right Grant
- 2004-09-16 RU RU2006113122/04A patent/RU2342373C2/ru active Protection Beyond IP Right Term
- 2004-09-16 ME MEP-117/08A patent/MEP11708A/xx unknown
- 2004-09-16 HR HRP20130322TT patent/HRP20130322T1/hr unknown
- 2004-09-16 ES ES04787385T patent/ES2403149T4/es not_active Expired - Lifetime
- 2004-09-16 RS RS20060189A patent/RS54614B1/sr unknown
- 2004-09-16 EP EP04787385A patent/EP1667986B1/fr not_active Expired - Lifetime
- 2004-09-16 RS YUP-2006/0189A patent/RS20060189A/sr unknown
- 2004-09-16 KR KR1020067005396A patent/KR101123588B1/ko not_active Expired - Lifetime
- 2004-09-16 DK DK04787385.6T patent/DK1667986T3/da active
- 2004-09-16 CA CA002539309A patent/CA2539309A1/fr not_active Abandoned
- 2004-09-16 NZ NZ545835A patent/NZ545835A/en not_active IP Right Cessation
- 2004-09-16 AU AU2004274212A patent/AU2004274212B2/en active Active
- 2004-09-17 TW TW093128097A patent/TWI382022B/zh not_active IP Right Cessation
- 2004-09-17 US US10/944,254 patent/US7241907B2/en not_active Expired - Lifetime
- 2004-09-17 MY MYPI20043787A patent/MY136668A/en unknown
-
2006
- 2006-03-09 IL IL174240A patent/IL174240A/en active IP Right Grant
- 2006-03-15 CR CR8292A patent/CR8292A/es unknown
- 2006-03-17 MA MA28881A patent/MA28045A1/fr unknown
- 2006-03-17 ZA ZA200602255A patent/ZA200602255B/en unknown
- 2006-03-17 TN TNP2006000086A patent/TNSN06086A1/en unknown
- 2006-04-19 NO NO20061714A patent/NO335997B1/no active Protection Beyond IP Right Term
-
2013
- 2013-03-20 LU LU92172C patent/LU92172I2/fr unknown
- 2013-04-16 CY CY20131100313T patent/CY1114575T1/el unknown
- 2013-05-13 CY CY2013016C patent/CY2013016I2/el unknown
- 2013-06-07 HU HUS1300025C patent/HUS1300025I1/hu unknown
- 2013-06-13 BE BE2013C036C patent/BE2013C036I2/fr unknown
- 2013-07-04 FR FR13C0037C patent/FR13C0037I2/fr active Active
-
2015
- 2015-04-22 NO NO2015013C patent/NO2015013I1/no not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US20020038038A1 (en) * | 1995-03-27 | 2002-03-28 | Aventis Pharma S.A. | Methods for treating pathological conditions of abnormal cell proliferation |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI382022B (zh) | 二甲氧基剋癌易（ｄｏｃｅｔａｘｅｌ）之丙酮溶劑合物及其製法 | |
| CN101918385A (zh) | 二甲氧基多西紫杉醇的结晶形式及其制备方法 | |
| JP2022069548A (ja) | ６’－シアリルラクトースナトリウム塩の結晶およびその製造方法 | |
| CN101652356A (zh) | 稳定的无水晶体多西他赛及其制备方法 | |
| JP3782449B2 (ja) | （２Ｒ，３Ｓ）−３−ベンゾイルアミノ−２−ヒドロキシ−３−フェニルプロピオン酸４，１０−ジアセトキシ−２α−ベンゾイルオキシ−５β，２０−エポキシ−１，７β−ジヒドロキシ−９−オキソ−タキセ−１１−エン−１３α−イル三水和物の製造法 | |
| WO2018067805A1 (en) | Solid state forms of sotagliflozin | |
| AU2020229932B2 (en) | Salt of aldose reductase inhibitor, and preparation method and application thereof | |
| AU2022230764A1 (en) | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor | |
| HK1093340B (en) | Dimethoxy docetaxel acetone solvate et method for the preparation thereof | |
| KR100429330B1 (ko) | 4,10β-디아세톡시-2α-벤조일옥시-5β,20-에폭시-1-하이드록시-9-옥소-19-노르-사이클로프로파[지]택스-11-엔-13α-일(2알,3에스)-3급-부톡시카보닐아미노-2-하이드록시-3-페닐프로피오네이트디하이드레이트및이의제조방법 | |
| EP2080763A1 (en) | Crystalline form I of ortataxel | |
| HK1141289A (en) | Stable anhydrous crystalline docetaxel and method for the preparation thereof | |
| JPWO2017195743A1 (ja) | ３’−シアリルラクトースナトリウム塩・ｎ水和物の結晶及びその製造方法 | |
| HK1131781A (en) | Crystalline form i of ortataxel | |
| MXPA97005460A (en) | Procedure for the preparation of trihydrate (2r, 3s) -3-benzoylamino-2-hydroxy-3-phenylpropionate de4, 10-diacetoxy-2alfa-benzoiloxi-5beta; 20-epoxy-1, 7beta-dihidroxi-9-oxo-tax -11-en-13alfa- |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |